Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock’s move reflects Neurocrine Biosciences’ (NASDAQ:NBIX) $53-per-share all-cash acquisition offer for Soleno. Investors are watching for any deal-related regulatory or closing risks. Trading volume reached 58 million shares, coming in about 2,148% above its three-month average of 2.6 million shares. Soleno Therapeutics IPO'd in 2014 and has fallen 96% since going public.
How the markets moved today
The S&P 500 gained 0.43% to finish Monday at 6,611, while the Nasdaq Composite added 0.54% to close at 21,996. Among biotechnology industry peers, Rezolute closed at $3.26, up 4.49%, and Ligand Pharmaceuticals ended at $203.61, rising 1.61%, as deal activity and drug data kept the group in focus.
What this means for investors
Neurocrine Biosciences reinforced its rare-disease drug portfolio on Monday, acquiring Soleno Therapeutics and its VYKAT XR treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). Soleno’s main drug, the first and only FDA-approved treatment for hyperphagia in patients with PWS, was launched in March 2025 and has delivered sales of $33 million, $66 million, and $92 million over the last three quarters.
Home to $2.5 billion in cash, Neurocrine’s offer of $2.9 billion for Soleno doesn’t break the bank and adds a third commercial drug for the biotech. VYKAT XR’s intellectual property should run through the 2040’s, adding serious long-term potential for Neurocrine. Trading at 18 times FCF, Neurocrine is an interesting stock to watch should this deal go through.
Should you buy stock in Soleno Therapeutics right now?
Before you buy stock in Soleno Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Soleno Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 6, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.
Recommended Articles
